Literature DB >> 1397023

Dopamine and melatonin in the nucleus accumbens may be implicated in the mode of action of antidepressant drugs.

C Durlach-Misteli1, J M Van Ree.   

Abstract

The effect of chronic systemic treatment (once a day for 2-3 weeks) with different antidepressant drugs (desipramine, mianserin, fluvoxamine 15 mg/kg per day i.p. or s.c.) on the behavioral responses elicited by intra-accumbens injection of graded doses (1-10,000 ng) of apomorphine and two doses (10 and 100 ng) of melatonin was investigated in rats. Treatment with antidepressant drugs consistently facilitated apomorphine-induced hypermotility, but differentially influenced apomorphine-induced hypomotility. The drugs completely antagonized melatonin-induced behavioral changes (hypomotility and increased duration of sniffing). The data suggest that chronic treatment with antidepressant drugs results in postsynaptic dopamine receptor supersensitivity in the nucleus accumbens, a terminal area of the mesolimbic dopaminergic system. It is postulated that the development of supersensitivity may be mediated by the inhibition of melatonin-induced effects observed after acute and chronic treatment with these antidepressants. The present findings may be relevant for the mode of therapeutic action of antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1397023     DOI: 10.1016/0014-2999(92)90505-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Melatonin effects on serotonin synthesis and metabolism in the striatum, nucleus accumbens, and dorsal and median raphe nuclei of rats.

Authors:  J M Míguez; F J Martín; M Aldegunde
Journal:  Neurochem Res       Date:  1997-01       Impact factor: 3.996

2.  Antipsychotics possessing antidepressive efficacy increase Golf protein in rat striatum.

Authors:  Hideki Taoka; Takashi Hamamura; Shiro Endo; Shinji Miyata; Kishio Toma; Takeshi Ishihara; Shigetoshi Kuroda
Journal:  Psychopharmacology (Berl)       Date:  2008-09-06       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.